Principal Financial Group Inc Phathom Pharmaceuticals, Inc. Transaction History

Principal Financial Group Inc

  • $172 Billion
  • Q4 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024
SELL
$6.21 - $11.05 $4,980 - $8,862
-802 Reduced 6.92%
10,783 $114,000
Q4 2023

Feb 07, 2024
SELL
$6.99 - $10.71 $1,509 - $2,313
-216 Reduced 1.83%
11,585 $105,000
Q3 2023

Nov 02, 2023
BUY
$10.26 - $15.7 $12,917 - $19,766
1,259 Added 11.94%
11,801 $122,000
Q2 2023

Aug 07, 2023
BUY
$7.28 - $14.32 $76,745 - $150,961
10,542 New
10,542 $150,000

Others Institutions Holding PHAT

# of Institutions
158
Shares Held
68.6M
Call Options Held
52.3K
Put Options Held
635K
View Full List

About Phathom Pharmaceuticals, Inc.

PHAT Quotes by TradingView
  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $244M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email